Filing Details

Accession Number:
0000932440-15-000125
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-04-02 11:00:15
Reporting Period:
2015-04-01
Filing Date:
2015-04-02
Accepted Time:
2015-04-02 11:00:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1437786 Immune Design Corp. IMDZ Pharmaceutical Preparations (2834) 262007174
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1033508 Jay Moorin C/O Proquest Investments
2430 Vanderbilt Beach Road, #108 - 190
Naples FL 34109
No No Yes No
1225149 Alain Schreiber C/O Proquest Investments
2430 Vanderbilt Beach Road, #108 - 190
Naples FL 34109
No No Yes No
1431818 Proquest Investments Iv, L.p.
2430 Vanderbilt Beach Road, #108 - 190
Naples FL 34109
No No Yes No
1431819 Proquest Associates Iv Llc
2430 Vanderbilt Beach Road, #108 - 190
Naples FL 34109
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-04-01 14,600 $25.51 2,399,440 No 4 S Direct
Common Stock Disposition 2015-04-01 39,819 $26.55 2,359,621 No 4 S Direct
Common Stock Disposition 2015-04-01 8,035 $27.07 2,351,586 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., each of whom may be deemed to have shared voting, investment and dispositive power with respect to these securities. Each individual managing member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
  2. Constitutes the weighted average sale price for multiple transactions reported on this line having prices per share ranging from $25.00 to $25.98. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
  3. Constitutes the weighted average sale price for multiple transactions reported on this line having prices per share ranging from $26.00 to $26.99. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
  4. Constitutes the weighted average sale price for multiple transactions reported on this line having prices per share ranging from $27.00 to $27.57. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.